410 related articles for article (PubMed ID: 19861435)
1. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.
Girard N; Shen R; Guo T; Zakowski MF; Heguy A; Riely GJ; Huang J; Lau C; Lash AE; Ladanyi M; Viale A; Antonescu CR; Travis WD; Rusch VW; Kris MG; Pao W
Clin Cancer Res; 2009 Nov; 15(22):6790-9. PubMed ID: 19861435
[TBL] [Abstract][Full Text] [Related]
2. Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets.
Enkner F; Pichlhöfer B; Zaharie AT; Krunic M; Holper TM; Janik S; Moser B; Schlangen K; Neudert B; Walter K; Migschitz B; Müllauer L
Pathol Oncol Res; 2017 Jul; 23(3):551-564. PubMed ID: 27844328
[TBL] [Abstract][Full Text] [Related]
3. Mutational status of EGFR and KIT in thymoma and thymic carcinoma.
Yoh K; Nishiwaki Y; Ishii G; Goto K; Kubota K; Ohmatsu H; Niho S; Nagai K; Saijo N
Lung Cancer; 2008 Dec; 62(3):316-20. PubMed ID: 18448188
[TBL] [Abstract][Full Text] [Related]
4. Systemic treatment of advanced thymic malignancies.
Kelly RJ
Am Soc Clin Oncol Educ Book; 2014; ():e367-73. PubMed ID: 24857125
[TBL] [Abstract][Full Text] [Related]
5. Thymic tumors: relevant molecular data in the clinic.
Girard N
J Thorac Oncol; 2010 Oct; 5(10 Suppl 4):S291-5. PubMed ID: 20859122
[TBL] [Abstract][Full Text] [Related]
6. [Therapy-relevant mutations of receptor tyrosine kinases in malignant thymomas and thymic carcinomas: a therapeutic perspective].
Ströbel P; Knop S; Einsele H; Müller-Hermelink HK; Marx A
Verh Dtsch Ges Pathol; 2007; 91():177-86. PubMed ID: 18314613
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Genomic Profiling of 274 Thymic Epithelial Tumors Unveils Oncogenic Pathways and Predictive Biomarkers.
Girard N; Basse C; Schrock A; Ramkissoon S; Killian K; Ross JS
Oncologist; 2022 Nov; 27(11):919-929. PubMed ID: 35749302
[TBL] [Abstract][Full Text] [Related]
8. Recurrent genetic aberrations in thymoma and thymic carcinoma.
Zettl A; Ströbel P; Wagner K; Katzenberger T; Ott G; Rosenwald A; Peters K; Krein A; Semik M; Müller-Hermelink HK; Marx A
Am J Pathol; 2000 Jul; 157(1):257-66. PubMed ID: 10880395
[TBL] [Abstract][Full Text] [Related]
9. Expression and mutational status of c-kit in thymic epithelial tumors.
Petrini I; Zucali PA; Lee HS; Pineda MA; Meltzer PS; Walter-Rodriguez B; Roncalli M; Santoro A; Wang Y; Giaccone G
J Thorac Oncol; 2010 Sep; 5(9):1447-53. PubMed ID: 20651610
[TBL] [Abstract][Full Text] [Related]
10. Absence of gene mutations in KIT-positive thymic epithelial tumors.
Tsuchida M; Umezu H; Hashimoto T; Shinohara H; Koike T; Hosaka Y; Eimoto T; Hayashi JI
Lung Cancer; 2008 Dec; 62(3):321-5. PubMed ID: 18486988
[TBL] [Abstract][Full Text] [Related]
11. Thymoma versus thymic carcinoma: differences in biology impacting treatment.
Kelly RJ
J Natl Compr Canc Netw; 2013 May; 11(5):577-83. PubMed ID: 23667207
[TBL] [Abstract][Full Text] [Related]
12. A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3.
Sakane T; Murase T; Okuda K; Saida K; Masaki A; Yamada T; Saito Y; Nakanishi R; Inagaki H
Histopathology; 2019 Nov; 75(5):755-766. PubMed ID: 31179560
[TBL] [Abstract][Full Text] [Related]
13. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors.
Suzuki E; Sasaki H; Kawano O; Endo K; Haneda H; Yukiue H; Kobayashi Y; Yano M; Fujii Y
Jpn J Clin Oncol; 2006 Jun; 36(6):351-6. PubMed ID: 16762968
[TBL] [Abstract][Full Text] [Related]
14. Molecular markers for patients with thymic malignancies: not feasible at present?
Avci N; Cecener G; Deligonul A; Erturk E; Tunca B; Egeli U; Tezcan G; Akyildiz EU; Bayram AS; Gebitekin C; Kurt E; Evrensel T
Asian Pac J Cancer Prev; 2014; 15(8):3457-60. PubMed ID: 24870739
[TBL] [Abstract][Full Text] [Related]
15. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas.
Meister M; Schirmacher P; Dienemann H; Mechtersheimer G; Schnabel PA; Kern MA; Herpel E; Xu EC; Muley T; Thomas M; Rieker RJ
Cancer Lett; 2007 Apr; 248(2):186-91. PubMed ID: 16919868
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors.
Nakagawa K; Matsuno Y; Kunitoh H; Maeshima A; Asamura H; Tsuchiya R
Chest; 2005 Jul; 128(1):140-4. PubMed ID: 16002927
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas.
Giaccone G; Rajan A; Ruijter R; Smit E; van Groeningen C; Hogendoorn PC
J Thorac Oncol; 2009 Oct; 4(10):1270-3. PubMed ID: 20197733
[TBL] [Abstract][Full Text] [Related]
18. COX-2 upregulation in thymomas and thymic carcinomas.
Rieker RJ; Joos S; Mechtersheimer G; Blaeker H; Schnabel PA; Morresi-Hauf A; Hecker E; Thomas M; Dienemann H; Schirmacher P; Kern MA
Int J Cancer; 2006 Nov; 119(9):2063-70. PubMed ID: 16823844
[TBL] [Abstract][Full Text] [Related]
19. Expression of proteasome subunit β5t in thymic epithelial tumors.
Yamada Y; Tomaru U; Ishizu A; Kiuchi T; Marukawa K; Matsuno Y; Kasahara M
Am J Surg Pathol; 2011 Sep; 35(9):1296-304. PubMed ID: 21836487
[TBL] [Abstract][Full Text] [Related]
20. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas.
Pan CC; Chen PC; Chiang H
J Pathol; 2004 Mar; 202(3):375-81. PubMed ID: 14991904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
